Kairos Pharma, Ltd.
KAPA · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $6 | $3 | $4 | $1 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $2 | $2 | $3 |
| Total Curr. Assets | $7 | $5 | $6 | $4 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $2 | $2 | $1 |
| Total NC Assets | $1 | $2 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $8 | $7 | $8 | $6 |
| Liabilities | – | – | – | – |
| Payables | $0 | $1 | $1 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $0 | $1 |
| Total Curr. Liab. | $0 | $1 | $1 | $1 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $0 | $1 | $1 | $1 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$13 | -$11 | -$10 | -$9 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $21 | $17 | $17 | $14 |
| Total Equity | $8 | $6 | $7 | $5 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $8 | $7 | $8 | $6 |
| Net Debt | -$6 | -$3 | -$4 | -$1 |